ChatGPT Health: Strategic Implications for Pharmaceutical Communications and Marketing

In the world of healthcare, innovation isn’t just expected, it’s essential; which is why at Spectrum Science, we’re constantly building, monitoring and seeking new tools that elevate scientific engagement and enhance patient experiences.

OpenAI’s announcement of ChatGPT Health this week represents a pivotal moment in the convergence of AI, digital health, and patient engagement—one that pharmaceutical and biotech marketers cannot afford to ignore. 

This innovation fits squarely at the intersection of three larger health trends including: the standardization of patient portals and electronic medical records where lab results are often provided to patients outside the confines of a clinical interaction, the rise of direct-to-patient (DTP) models, like HIMS and HERS, and the proliferation of health wearables and apps. It is the natural evolution of the shift in health-seeking information from traditional to generative search. We can now firmly assume that the first step in most patient journeys is an AI conversation.

With over 230 million people already asking health-related questions on ChatGPT weekly, this dedicated health experience creates both unprecedented opportunities and complex challenges for how we engage with patients, drive disease awareness, and position our brands in an increasingly AI-mediated healthcare landscape. Pharma brands must consider how their educational content, support resources, and patient services integrate into these emerging digital ecosystems, where patients expect seamless digital access to health information and the ability to make sense of it without waiting for a provider appointment.

While there’s much to still learn, here are some initial implications, opportunities and risks to be aware of:

Specific Potential Opportunities

Opportunity 1: Enhanced Disease Awareness and Diagnosis Support: ChatGPT Health’s ability to analyze personal health data, identify patterns, and flag potential concerns could dramatically accelerate disease awareness and earlier diagnosis—particularly for underdiagnosed and rare conditions.

• Strategic Action: Partner with patient advocacy groups to educate about using AI tools safely to track symptoms and prepare for medical consultations. Create evidence-based content that helps train AI systems to recognize early signs of conditions your therapies address.

Opportunity 2: Patient Education and Engagement at Scale: ChatGPT Health provides 24/7 conversational access to health information—filling the gap between doctor visits and enabling patients to better understand their conditions and treatment options.

• Strategic Action: Develop high-quality, medically accurate educational content specifically designed for AI consumption and synthesis. Consider creating “AI-optimized” versions of patient support materials that can be reliably referenced by conversational AI systems. In other words, Generative Engine Optimization (GEO) must become standard across all programs, properties and materials. Learn more about GEO, here.

Opportunity 3: Deeper connections between Health and Lifestyle Data: With the proliferation of apps and wearables, lifestyle factors and self-reported metrics sit alongside lab values and clinical notes in informing health decisions. ChatGPT Health promises to seamlessly connect and further “consumerize” all of these inputs.

• Strategic Action: Pharma marketing must consider the broader context of how patients live, move, eat and sleep as part of their journey. Engagement strategies  should connect therapeutic interventions with a more holistic view of patient health that extends beyond symptoms and diagnosis to include lifestyle factors, behavioral patterns, and wellness metrics

Opportunity 4: Direct Digital Engagement Channels: As pharmaceutical marketing trends toward direct-to-patient (DTP) models and omnichannel strategies, AI platforms represent a new, high-engagement channel for reaching patients in the natural language ways they have become accustomed to engaging.

• Strategic Action: Build expertise in AI-mediated patient engagement before it becomes table stakes. Explore and pilot AI powered education and engagement through existing patient support programs or clinical trial recruitment platforms.

Opportunity 5: Partnership and sponsorship opportunities on the horizon: Sources predict that OpenAI will roll out advertising opportunities on the platform in the second half of 2026. OpenAI has said: Advertising will not influence core ChatGPT responses or rankings, premium subscribers (Plus/Pro) will remain ad-free, and focus will be on “contextual relevance” rather than intrusive formats.

• Strategic Action: As ChatGPT Health scales, keep an eye out for partnership models may emerge including therapeutic area content partnerships, data integration partnerships with patient support programs or clinical trial integrations.

Potential Risks to be Aware of

We recognize ChatGPT Health as a promising platform for transforming healthcare accessibility. However, our commitment to clients requires acknowledging critical unresolved questions: data privacy safeguards are unclear; regulatory frameworks are undefined; liability protections are absent or fragmented; and language models carry inherent limitations. We remain optimistic about AI in healthcare and support innovations that demonstrate compliance, offer robust privacy protection, and are accountable to those they serve. 

Risk 1. Privacy and Data Security Concerns 

GPT conversations are not HIPAA compliant: As privacy advocates have noted, health data shared with AI tools often falls outside U.S. medical privacy laws. When held by doctors or insurance companies, health data receives HIPAA protection; when held by AI companies, app developers, or wearable manufacturers, it does not. We should note that this launch excludes the European Economic Area (EEA), Switzerland, and the UK. While not stated explicitly, we can assume that is because this offering does not square with General Data Protection Regulation (GDPR) that governs handling of data in these geographies. 

Key Concerns: 

• Patients in the U.S. may not understand the distinction between HIPAA-protected and non-protected health data 

• OpenAI shares user data with third parties “in certain circumstances” and can share with law enforcement when required by law 

• No federal comprehensive privacy law governs health data held by technology companies in the U.S. 

• The burden of evaluating data privacy falls entirely on individual consumers 

What This Means for Pharma: 

• Any partnerships or integrations with ChatGPT Health must be carefully evaluated for regulatory compliance 

• Patient trust could be damaged if data breaches or misuse occur 

• Pharma companies must be transparent about how patient data flows when they create digital touchpoints that might feed into AI platforms 

Risk 2. Accuracy and Medical Misinformation Risks 

Accuracy is more important in healthcare than in any other realm: Patients may act on AI-generated health advice that is incomplete, contextually inappropriate, or simply wrong—potentially delaying appropriate care or making harmful treatment decisions. 

Large language models operate by predicting likely responses, not by accessing verified medical knowledge databases. They are prone to “hallucinations”—confidently stating incorrect information and, while OpenAI explicitly states ChatGPT is “not intended for use in the diagnosis or treatment of any health condition.” We should assume that it may be used as such. 

What This Means for Pharma: 

• Disease awareness campaigns must compete with AI-generated health information that may be inaccurate 

• Patients may arrive at HCP appointments with AI-influenced assumptions that need to be addressed 

• Pharma brands must consider how to validate and potentially correct misinformation spread through AI channels
• Biopharma and technology companies must consistently reinforce the boundaries between empowerment and clinical decision-making 

Risk 3. Competitive Landscape and Access 

Who controls the patient relationship and what are their motives? With regulation lagging way behind the use of generative engines, there are inherent risks in putting a technology —motivated to keep users engaged with it at all costs— at the center of health discussions.  If ChatGPT Health becomes the primary interface through which patients understand their health, OpenAI effectively becomes a gatekeeper that may introduce bias and very real risk. Real life scenarios of ChatGPT further isolating vulnerable users without appropriate guardrails is, in fact, already the focus of several troubling wrongful death/suicide lawsuits.  

Questions arise: 

• Which therapeutic options does ChatGPT Health recommend or prioritize? 

• How are treatment comparisons presented? 

• Could sponsored content or partnerships create bias in AI recommendations? 

• Could ChatGPT further disconnect patients from their ecosystem of community and clinical support and might this disproportionately impact those already disenfranchised from the current health system in the US, in particular?  

What this means for pharma: Pharma companies face a tension between wanting to reach patients where they are (increasingly, on AI platforms) and concerns about losing direct relationships and brand message control, as well as taking on unforeseen liability. 

In conclusion, generative engine search about health, now codified by the launch of ChatGPT Health is not a trend to monitor from a distance—it’s a transformation that’s already reshaping how 230 million people engage with health information each week.

Immediate Actions You Can Take 

• Educate Your Organization: Brief leadership, medical affairs, and commercial teams on ChatGPT Health and its implications and embrace AI as a channel 

• Audit Digital Assets: Review patient-facing content for “AI findability”— is it structured, accurate, and likely to be correctly synthesized by AI systems? Engage with Spectrum to kick off or continue GEO efforts 

• Assess Regulatory Implications: Work with legal and compliance to understand how AI platforms fit within promotional guidelines, patient data regulations and risk mitigation 

• Monitor Patient Adoption: Track how your patient populations are using ChatGPT Health through social listening and patient feedback 

At Spectrum, our purpose has always been to connect humankind to its best healthlife. Our role is to shape communications on behalf of healthcare innovators that deliver clarity, accuracy, empathy and relevance to patients and HCPs.

We’re continuing to lean in with the belief that AI is a powerful platform to help advance human health. As the tools to communicate and educate evolve, so must our strategy, creativity and responsibility as communicators. If you’re interested in learning more about how you can leverage ChatGPT Health to drive momentum for your business or brands, please reach out.  

++

Bonus Content: Details of What ChatGPT Health Offers and Claims re: Privacy and HCP partnership

ChatGPT Health is a dedicated, compartmentalized experience within ChatGPT that allows users to:

Core Capabilities

• Connect medical records and health data through partnership with b.well Connected Health infrastructure 

• Integrate with wellness apps including Apple Health, MyFitnessPal, Weight Watchers, AllTrails, Instacart, and Peloton 

• Receive personalized health insights grounded in their own health data 

• Understand lab results, prepare for doctor appointments, and navigate treatment decisions 

• Access nutrition advice, workout recommendations, and insurance option comparisons 

Key Differentiators

• Enhanced Privacy Architecture: Purpose-built encryption and data isolation keep health conversations separate from other ChatGPT interactions 

• No Model Training: Health conversations are explicitly not used to train OpenAI’s foundation models 

• Clinical Validation: Developed over two years with 260+ physicians from 60 countries 

• HealthBench Evaluation: The model has been evaluated against clinical standards using OpenAI’s proprietary benchmark focused on safety, clarity, and care escalation 

Important Limitations

• Not HIPAA compliant (consumer health apps fall outside HIPAA coverage) 

• Explicitly not intended for diagnosis or treatment 

• Designed to support, not replace, medical care 

• Currently available only outside the EEA, Switzerland, and UK 

++

Update: January 13

A few notes on the flurry of news on healthcare-specific large language models coming out of this year’s JP Morgan Healthcare Conference week: 

You may have noticed that hot on the heels of the ChatGPT Health announcement, Open AI announced a new healthcare enterprise product suite called Open AI for Healthcare —comprised of OpenAI API, a developer platform for engineers building custom healthcare tools and ChatGPT Healthcare, a compliant clinician-facing workspace for hospitals, health systems, payers, academic medical centers, and large healthcare enterprises). 

Competitor Anthropic, maker of AI model Claude, built on their introduction last fall of Claude for Life Sciences—a chatbot style research partner for life science companies— to introduce Claude for Healthcare, expanding their health-specific offering to consumers, HCPs, hospitals and payers.

In a nutshell, OpenAI and Anthropic are pursuing nearly identical dual-tracks. Along with consumer models (neither HIPAA compliant and only available in the US), both companies’ enterprise offerings (OpenAI for Healthcare and Claude for Healthcare) include HIPAA-ready infrastructure (likely also GDPR compliant) with Business Associate Agreements, enabling them to handle protected health information in clinical workflows. But the companies are pursuing two different go-to-market strategies. In short, Open AI is pursuing consumer familiarity leading to enterprise adoption, where Anthropic is pursuing enterprise trust— which they hope will lead to consumer expansion.  

As always, we’ll be keeping a close eye on how these offerings overlap and differ as we are able to learn more about them. It’s important to note, too, that Google is expected to follow with a similar announcement soon, particularly given its October 2025 partnership with b.well (the same health data infrastructure provider OpenAI uses for ChatGPT Health).